CV and publications



  • Name: Peder Rustøen Braadland
  • Date of birth: 11.12.1988
  • Nationality: Norwegian
  • Married?
  • Children? 3x

SHORT INTRODUCTION

I hold a MS in biotechnology and a PhD in molecular biology, but have strong interests in (bio)statistical modeling and coding and data visualization in rstats. I’m currently employed at the Norwegian PSC Research Center (NoPSC) at Rikshospitalet, Oslo, Norway.

My main research agenda is on the gut-liver axis in primary sclerosing cholangitis (PSC), which is a significant part of my group’s agenda. In close collaboration with experts in biochemistry and cell-based model systems, we work on discovering gut microbially produced metabolites that influence the development and course of PSC.

EDUCATION

  • 2020: PhD, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway
  • 2013 - Master, Department of Biotechnology and Food Science, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

KEY SKILLS

  • R (tidyverse, rms, survival, RMarkdown, Quarto)
  • Data visualization (ggplot2, Illustrator)
  • Bioinformatics and biostatistics (regression modeling, statistical theory, study design)
  • Graphical design (Photoshop, Illustrator)

SPOKEN LANGUAGES

  • Norwegian (fluent verbal and written communication skills)
  • English (fluent verbal and written communication skills)
  • German (proficient verbal, intermediate written)

EXPERIENCE

  • Co-supervisor PhD (S. Tjønnfjord) 2023-present (University of Oslo)
  • Co-supervisor PhD (M. J. Hole) 2022-present (University of Oslo)
  • Co-supervisor for a MSc student 2017-2018 (Oslo University Hospital)

RELEVANT COURSES

  • Statistical Methods for Risk Prediction and Prognostic Models. March 2023 (University of Birmingham)
  • Prognosis Research in Health Care: Concepts, Methods and Impact. July 2022 (Keele University)

CURRENT AND PREVIOUS POSITIONS

  • 2020 – current: Postdoctoral fellow at the Norwegian PSC Research Center, University of Oslo
  • 2016 – 2020: PhD student, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway
  • 2013 – 2015: Faculty, Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital

FELLOWSHIPS AND REWARDS

  • 2017: Best scientific presentation, Norsk Urologisk Forening, Fall meeting 2017

CAREER BREAKS

  • March 2024 – June 2024: Parental leave
  • September 2019 – June 2020: Parental leave
  • June 2017 – September 2017: Parental leave

List of publications

Shows only peer-reviewed, original research and review articles.

Last updated 2025-07-22

Article citations
PR Braadland, HH Grytli, H Ramberg, B Katz, R Kellman, ... (2015). Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. Oncotarget. 7 (2), 1878. 11
PR Braadland, H Ramberg, HH Grytli, KA Taskén (2015). β-adrenergic receptor signaling in prostate cancer. Frontiers in oncology. 4, 375. 88
PR Braadland, G Giskeødegård, E Sandsmark, H Bertilsson, LR Euceda, ... (2017). Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. British journal of cancer. 117 (11), 1656-1664. 44
PR Braadland, A Urbanucci (2019). Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer. Endocrine-related cancer. 26 (4), R211-R235. 26
PR Braadland, H Ramberg, HH Grytli, A Urbanucci, HK Nielsen, ... (2019). The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. Molecular Cancer Research. 17 (11), 2154-2168. 34
A Serguienko, P Braadland, LA Meza-Zepeda, B Bjerkehagen, ... (2020). Accurate 3-gene-signature for early diagnosis of liposarcoma progression. Clinical Sarcoma Research. 10 (1), 4. 8
IJ Guldvik, V Zuber, PR Braadland, HH Grytli, H Ramberg, W Lilleby, ... (2020). Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification. European urology open science. 21, 51-60. 23
H Ramberg, E Richardsen, GA de Souza, M Rakaee, ME Stensland, ... (2021). Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer. Carcinogenesis. 42 (5), 685-693. 17
IJ Guldvik, PR Braadland, S Sivanesan, H Ramberg, G Kristensen, ... (2022). Low blood levels of LRG1 before radical prostatectomy identify patients with high risk of progression to castration-resistant prostate cancer. European Urology Open Science. 45, 68-75. 3
PR Braadland, KM Schneider, A Bergquist, A Molinaro, ... (2022). Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis. JHEP Reports. 4 (11), 100561. 18
MJ Hole, KK Jørgensen, K Holm, PR Braadland, MH Meyer‐Myklestad, ... (2023). A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation. Hepatology. 77 (3), 715-728. 34
PR Braadland, A Bergquist, M Kummen, L Bossen, LK Engesæter, ... (2023). Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation. Journal of Hepatology. 79 (4), 955-966. 10
SC Raju, A Molinaro, A Awoyemi, SF Jørgensen, PR Braadland, A Nendl, ... (2024). Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity. Genome medicine. 16 (1), 27. 21
W Lin, L Gerullat, PR Braadland, A Fournier, JR Hov, D Globisch (2024). Rapid and Bifunctional Chemoselective Metabolome Analysis of Liver Disease Plasma Using the Reagent 4‐Nitrophenyl‐2H‐azirine. Angewandte Chemie International Edition. 63 (14), e202318579. 4
MM Grimsrud, M Forster, B Goeppert, G Hemmrich-Stanisak, I Sax, ... (2024). Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis. Hepatology Communications. 8 (7), e0461. 3
Note:
Shows only peer-reviewed articles and pre-prints

Cumulative publications

Timeline

Overall citations

[1] 10

Theses

  • Braadland, P. R. (2020). Targeting therapy resistance in advanced prostate cancer (PhD thesis)

  • Braadland, P. R. (2013). Prostate Cancer Metabolism: Effects of β2-Adrenergic Receptor Knockdown in LNCaP Cells. Institutt for bioteknologi (Master thesis)